Form 4: Syros Pharmaceuticals Director Akkaraju Srinivas Reports Stock Transactions
SEC Form 4
Director Akkaraju Srinivas of Syros Pharmaceuticals reports the vesting of restricted stock units and subsequent disposal of shares.
Summary
- On September 16, 2024, Akkaraju Srinivas, a director of Syros Pharmaceuticals, had 2,667 restricted stock units (RSUs) vest.
- Upon vesting, these RSUs converted into 2,667 shares of common stock.
- Simultaneously, Mr. Akkaraju disposed of 9,333 shares of common stock.
- Following these transactions, Mr. Akkaraju continues to beneficially own 2,667 derivative securities.
Sentiment
Score: 5
Explanation: This is a neutral event. It's a routine disclosure of stock transactions by a company insider. The vesting of RSUs is part of a compensation plan, and the subsequent sale is a personal financial decision.
Industry Context
This is a standard SEC Form 4 filing, which is a routine disclosure for corporate insiders who have transacted in their company's stock. It provides transparency to the market regarding insider activity.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the overall impact is likely minimal.
Key Dates
| Date | Description |
|---|---|
| September 16, 2022 | Date of grant for the restricted stock unit award. |
| September 16, 2023 | Commencement date for the vesting of restricted stock units in three equal annual installments. |
| September 16, 2024 | Date of transaction: vesting of 2,667 restricted stock units and disposal of 9,333 shares. |
| September 18, 2024 | Date of signature for the Form 4 filing. |
Keywords
Syros Pharmaceuticals, Director, Stock Transaction, Form 4, RSU, Vesting, Common Stock, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.